12:00 AM
 | 
Feb 06, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Amitiza lubiprostone: Phase III data

A double-blind, international Phase III trial in 439 patients showed that twice-daily 24 ug lubiprostone met the primary endpoint of a significantly greater overall SBM response rate vs. placebo at week 12 (26.9% vs. 18.6%, p=0.035). No drug-related serious adverse events were reported, while diarrhea, nausea, and abdominal pain were reported as the most...

Read the full 248 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >